Leisure Capital Management increased its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 6.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,936 shares of the biopharmaceutical company’s stock after purchasing an additional 223 shares during the quarter. Leisure Capital Management’s holdings in Bristol-Myers Squibb were worth $219,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of BMY. Ameriprise Financial Inc. grew its holdings in Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares during the last quarter. Swiss National Bank grew its holdings in Bristol-Myers Squibb by 27.2% in the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares during the last quarter. State Street Corp grew its holdings in Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares during the last quarter. Jennison Associates LLC grew its holdings in Bristol-Myers Squibb by 5.4% in the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after acquiring an additional 1,184,652 shares during the last quarter. Finally, Harbour Capital Advisors LLC grew its holdings in Bristol-Myers Squibb by 5,377.1% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,189,789 shares of the biopharmaceutical company’s stock worth $21,353,000 after acquiring an additional 1,168,066 shares during the last quarter. Institutional investors own 68.97% of the company’s stock.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.23% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Leisure Capital Management Has $219,000 Position in Bristol-Myers Squibb Company (BMY)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/23/leisure-capital-management-has-219000-position-in-bristol-myers-squibb-company-bmy.html.

A number of equities research analysts have issued reports on BMY shares. Credit Suisse Group reissued a “hold” rating and issued a $61.00 price target (up previously from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Cowen and Company reissued a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Jefferies Group LLC raised their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Finally, Leerink Swann raised their price target on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $64.93.

Shares of Bristol-Myers Squibb Company (BMY) opened at $61.14 on Thursday. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The company has a market cap of $100,231.52, a PE ratio of 20.69, a P/E/G ratio of 2.41 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the previous year, the firm earned $0.77 EPS. The company’s revenue was up 6.7% on a year-over-year basis. analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.